<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330042</url>
  </required_header>
  <id_info>
    <org_study_id>IRB#00010949</org_study_id>
    <nct_id>NCT02330042</nct_id>
  </id_info>
  <brief_title>OCT Biomarkers for Diabetic Retinopathy</brief_title>
  <official_title>Functional Optical Coherence Tomography-Derived Biomarkers for Diabetic Retinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <brief_summary>
    <textblock>
      Diabetic retinopathy (DR) is caused by changes in the blood vessels of the retina associated
      with long-term Type 1 or Type 2 diabetes mellitus. DR is a leading cause of blindness in the
      United States. Standard optical coherence tomography (OCT) cannot directly detect vascular
      changes, which may occur early affecting the passage of blood through the tiny capillaries
      (reduced capillary flow) or cause the greatest damage through formation of abnormal blood
      vessel growth (neovascularization). Currently, fluorescein angiography (FA) is the gold
      standard for detecting these changes, but FA requires an injection of a dye into the vein of
      the arm of the patient. This dye can cause undesirable side effects. Recently, OCT has been
      used to make functional measurements (such as total retinal blood flow among others) and to
      perform angiography. Thus, functional OCT may provide a useful, alternate way to evaluate
      diabetic retinopathy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with decreased total retinal blood flow by OCT angiography</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with capillary dropout and/or new abnormal retinal blood vessel growth by OCT angiography</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with measureable macular edema by OCT imaging</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">215</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <description>Patients with:
Type 1 or Type 2 diabetes mellitus
severe non-proliferative diabetic retinopathy (NPDR) or proliferative diabetic retinopathy (PDR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <description>Patients with:
Type 1 or Type 2 diabetes mellitus
with or without mild to moderate NPDR</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C (controls)</arm_group_label>
    <description>Patients without diabetes or evidence of any form of eye disease</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with Type 1 diabetes of greater than 5 years duration OR Type 2 diabetes of
        any duration. Healthy controls are also being enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria for participants with diabetes:

          -  Male or female participants 18-79 years old

          -  With Type 1 diabetes for over 5 years or Type 2 diabetes of any duration

        Exclusion Criteria for participants with diabetes:

          -  Vision worse than 20/200

          -  Inability to maintain fixation for OCT imaging

          -  Significant kidney disease, kidney failure or kidney transplant

          -  Unstable medical status, including blood pressure greater than 180/110 or unstable
             heart disease

          -  Pregnant or nursing an infant

          -  Presence of an eye disease (other than diabetic retinopathy) that can affect retinal
             blood flow, retinal permeability or retinal anatomy

          -  Significant cataract, corneal scar, vitreous bleed or other media opacity

          -  History of major eye surgery within 4 months prior to enrollment in this study

        Inclusion Criteria for participants without diabetes (controls):

          -  Male or female participants 18-79 years old

        Exclusion Criteria for participants without diabetes (controls):

          -  Vision worse than 20/200

          -  Inability to maintain fixation for OCT imaging

          -  Significant kidney disease, kidney failure or kidney transplant

          -  Unstable medical status, including blood pressure greater than 180/110 or unstable
             heart disease

          -  Pregnant or nursing an infant

          -  Presence of any eye disease that can affect retinal blood flow, retinal permeability
             or retinal anatomy

          -  Significant cataract, corneal scar, vitreous bleed or other media opacity

          -  History of major eye surgery within 4 months prior to enrollment in this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Hwang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Poole, COT</last_name>
    <phone>503-494-8024</phone>
    <email>pooleb@ohsu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Denzil Romfh, OD</last_name>
    <phone>503-494-4351</phone>
    <email>romfhd@ohsu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Poole, COT</last_name>
      <phone>503-494-8024</phone>
      <email>pooleb@ohsu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Denzil Romfh, OD</last_name>
      <phone>503-494-4351</phone>
      <email>romfhd@ohsu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas Hwang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Andreas Lauer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christina Flaxel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steve Bailey, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Klein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Phoebe Lin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Wilson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yali Jia, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ou Tan, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lorinna Lombardi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ellen Davis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seema Gupta, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 30, 2014</study_first_submitted>
  <study_first_submitted_qc>December 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2015</study_first_posted>
  <last_update_submitted>April 10, 2018</last_update_submitted>
  <last_update_submitted_qc>April 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>David Huang</investigator_full_name>
    <investigator_title>Yali Jia, PhD, Research Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>OCT</keyword>
  <keyword>Angiography</keyword>
  <keyword>Diabetic retinopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

